FOI 2024-192

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage) :

·       Avelumab + Axitinib - <5

·       Axinitib - NIL

·       Cabozantinib - <5

·       Everolimus - NIL

·       Lenvatinib + Everolimus - NIL

·       Lenvatinib + Pembrolizumab - 6

·       Nivolumab monotherapy - 5

·       Nivolumab + Cabozantinib - NIL

·       Nivolumab + Ipilimumab - <5

·       Pazopanib - NIL

·       Pembrolizumab monotherapy - NIL

·       Pembrolizumab + Axitinib - NIL

·       Radiotherapy only - N/A – service not offered at ELHT.

·       Sunitinib - <5

·       Temsirolimus - NIL

·       Tivozanib - 5

·       Other active systemic anti-cancer therapy - NIL

·       Palliative care only – <5

Q2. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Jan – March is the latest fully coded position

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

·       Nivolumab (monotherapy) - <5

·       Nivolumab + Ipilimumab - NIL

·       Nivolumab + Cabozantinib -  NIL

• Lenvatinib + Pembrolizumab - NIL

·       Avelumab + Axitinib - NIL

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q4. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?

NIL - no studies, zero recruits.

​​​​​​​